Business
Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.
(TheNewswire) May 14, 2025 – TheNewswire - Toronto, Ontario – ...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n May 14, 2025 –\n \n\n TheNewswire -\n \n\n Toronto, Ontario\n \n\n –\n \n\n Helix BioPharma Corp.\n \n\n (TSX:\n \n\n “HBP”\n \n\n , OTC PINK:\n \n\n “HBPCD”\n \n\n ,\nFRANKFURT:\n \n\n “HBP0”\n \n\n ) (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage oncology company shaping a near future\nwhere today’s hard-to-treat cancers are vincible, announced today\nthat it has signed an agreement with Kerentech Consulting Ltd.\n(\n \n\n “Kerentech”\n \n\n ), under which Kerentech will support Helix in its ongoing\nfundraising efforts.\n \n\n\n\n Under the terms of the agreement, Kerentech\n \n\n will assist Helix in closing a bridge financing\nround of USD 13 million to advance the company’s lead therapeutic\nprograms and strategic priorities through 2025 and beyond. The\ncollaboration reflects Helix’s commitment to accelerating efforts to\nsecure a stable financial platform and fast-track the development of\nits pipeline candidates this year, beginning with its lead candidate,\nTumor Defense Breaker™ L-DOS47.\n \n\n\n\n “We’re pleased to team up with Kerentech as we\ndouble down on our efforts to deliver meaningful progress in tackling\nhard-to-treat cancers as rapidly as possible,”\n \n\n said Thomas Mehrling, MD, PhD, Chief\nExecutive Officer of Helix\n \n\n BioPharma\n \n\n . “We’re seeing strong engagement\nfrom investors and are focused on bringing this round to a timely\nclose —so we can accelerate the clinical development of L-DOS47 in\ncombination with an immune checkpoint inhibitor and push toward better\noutcomes in non-small cell lung cancer.”\n \n\n\n\n About Kerentech Consulting Ltd.\n \n\n\n\n Kerentech Consulting Ltd. is a global advisory firm\nspecializing in strategic fundraising and corporate development for\nemerging life sciences and healthcare companies. With deep industry\nexpertise and a robust investor network, Kerentech helps clients\nunlock capital, accelerate growth, and navigate critical inflection\npoints with confidence. The firm provides tailored support across\ne...